Roland Fenk
Prof. Dr
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731 ) resulted in a significant increase of minimal residual disease negativity (MRD–) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide. We report updated results for part 1 from first random assignment to post-transplant. As of January 31, 2024, MRD– rates continued to deepen after transplant (66% Isa-RVd v 48% RVd). Isa-RVd induction therapy significantly prolonged progression-free survival (PFS) compared with RVd regardless of maintenance therapy (hazard ratio, 0.70 [95% CI, 0.52 to 0.95]; P = .0184). Weighted risk set estimator analysis accounting for second random assignment followed by maintenance with only lenalidomide confirmed a statistically significant benefit for Isa-RVd followed by lenalidomide maintenance versus RVd followed by lenalidomide maintenance (stratified weighted log-rank test P = .016). In conclusion, after 18-week induction therapy followed by transplant without consolidation therapy, adding Isa to RVd resulted in a significant PFS benefit, regardless of maintenance strategy.
Year:
2025
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
Year:
2025
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
Year:
2025
Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. In this study, we interrogated 580 whole-genome sequence (WGS) samples from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose–response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode, we demonstrate that a single RT-surviving cell may seed distant relapse. Significance: RT and the ID8 indel signature are related, but their genomic impact on hematologic malignancies is unclear. Leveraging WGS, we linked ID8 to both RT and mutagenic chemotherapy and validated that platinum can induce ID8. We used ID8 as a genomic barcode to reveal that RT-resistant cells may seed systemic relapse.
Year:
2025
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
Year:
2025
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
Year:
2025
Collaborators (12)
Karolin Trautmann-Grill
University Hospital Carl Gustav Carus
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Jonathan Schatz
Associate Professor
University of Miami School of Medicine
Bachisio Ziccheddu
Sylvester Comprehensive Cancer Center, University of Miami
Tobias Holderried
Professor of Cellular Immunotherapy
Medical University of Graz
Christian Sebastian Michel
Attending physician, Head of Myeloma Service
University Medical Center of the Johannes Gutenberg University Mainz
Katja C. Weisel
University Medical Center Hamburg-Eppendorf
Saad Usmani
Chief Attending
Memorial Sloan Kettering Cancer Center
Tomas Jelinek
-
Michael Jain
Associate Member
H Lee Moffitt Cancer Center and Research Institute
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Marc S. Raab
University Hospital Heidelberg
Make your next move.
Prepare your application
Review drafts before you send them.